Skip to Main Content

In a little noticed warning, the Food and Drug Administration threatened to fine the principal investigator of a clinical trial for failing to submit results as required by federal law, marking the first time the agency has widened its list of targets that could face penalties for such a violation.

Until now, the regulator had warned two different drug makers for failing to post study results to a federal database, Those moves came as a belated response to years of complaints that too many drug makers and universities do not follow requirements for reporting results, an issue that has riled countless researchers and transparency advocates.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment